Caliway Biopharmaceuticals’ Post

Caliway's first Phase 2 study results announcement in 2024! CBL-0201EFP Phase 2 study demonstrated CBL-514 statistically significant efficacy in reducing #cellulite severity scores at 4 and 12 weeks after treatment, moreover, over 50% of participants experienced at least 1 level of improvement in cellulite severity. For detailed topline results, please visit:

Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints-Caliway Biopharmaceuticals Co., Ltd

Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints-Caliway Biopharmaceuticals Co., Ltd

caliway.com.tw

Andersen Lin

Head of Quality Center at Focaltech

8mo

Amazing achievement. Congratulations to Caliway and teams !

To view or add a comment, sign in

Explore topics